Lactobacillus casei Variety rhamnosus Probiotic Preventively Attenuates 5-Fluorouracil/Oxaliplatin-Induced Intestinal Injury in a Syngeneic Colorectal Cancer Model
Ching-Wei Chang,Chia-Yuan Liu,Hung-Chang Lee,Yen-Hua Huang,Li-Hui Li,Jen-Shiu Chiang Chiau,Tsang-En Wang,Cheng-Hsin Chu,Shou-Chuan Shih,Tung-Hu Tsai,Yu-Jen Chen
DOI: https://doi.org/10.3389/fmicb.2018.00983
IF: 5.2
2018-05-15
Frontiers in Microbiology
Abstract:Adjuvant 5-fluorouracil (5-FU)-based chemotherapy, including FOLFOX (5-FU, leucovorin, and oxaliplatin), is recommended for colorectal cancer. However, intestinal mucositis remains a common adverse effect for which no effective preventive strategies are available. To develop a convenient and novel way to alleviate mucositis, we investigated the effect of <i>Lactobacillus casei</i> variety <i>rhamnosus</i> (<i>Lcr35</i>) on FOLFOX-induced mucosal injury. BALB/c mice subcutaneously injected with syngeneic CT26 colorectal adenocarcinoma cells were orally administered <i>Lcr35</i> daily before, during, and after 5-day injection of FOLFOX regimen, for 14 days. The following methods were used: diarrhea score for toxicity, ELISA for cytokine production, histopathology for intestinal injury, immunohistochemistry for apoptosis/proliferation and regulatory proteins, RT-PCR for cytokine mRNA expression, and DNA sequencing for fecal gut microbiota. FOLFOX administration to colorectal cancer-bearing mice significantly inhibited tumor growth and the accompanying marked diarrhea and intestinal injury histologically characterized by the shortening of villi and destruction of intestinal crypts. Preventive administration of <i>Lcr35</i> dose-dependently reduced the severity of diarrhea and intestinal mucositis without affecting the anti-tumor effect of FOLFOX. The numbers of apoptotic, NF-κB-, and BAX-activated cells increased after FOLFOX, and these responses were mitigated by <i>Lcr35</i>. TNF-α and IL-6 upregulation by FOLFOX treatment was attenuated by <i>Lcr35</i>. The fecal gut microbiota composition of <i>Firmicutes</i> and <i>Bacteroidetes</i> disturbed by FOLFOX was significantly reversed by <i>Lcr35</i> toward a preferential profile. In conclusion, the oral probiotic <i>Lcr35</i> prevented FOLFOX-induced intestinal mucositis in colorectal cancer-bearing mice. The putative mechanism might involve modulation of gut microbiota and proinflammatory responses with suppression of intrinsic apoptosis in intestinal injury.
microbiology